Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications.
Genentech Inc and Novartis Ophthalmics AG have developed and launched the humanized anti-VEGF antibody fragment ranibizumab, a 48-kDa humanized antibody fragment that inhibits all forms of biologically active VEGF-A, for the treatment of age-related macular degeneration by intravitreal administration. Phase I to III clinical trials to confirm the role of ranibizumab in the treatment of choroidal neovascularization (phase II and III), diabetic macular edema (phase II and III), retinal venous occlusion (phase II and III), telangiectasia (phase I and II), central serous chorioretinopathy (phase I), polypoidal choroidal vasculopathy (phase I/II), conjunctival neoplasms (phase I) and von Hippel-Lindau syndrome (phase I) are ongoing.
Bracco Research USA, NJ 08540, USA. laura.lantry@bru.bracco.com
Laura E
LE
Lantry
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization; D002986:Clinical Trials as Topic; D003230:Conjunctival Neoplasms; D048909:Diabetes Complications; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000069579:Ranibizumab; D013684:Telangiectasis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D006623:von Hippel-Lindau Disease
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab